These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Evaluation of early response to hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma using the combination of response evaluation criteria in solid tumors and tumor markers. Miyaki D; Kawaoka T; Aikata H; Kan H; Fujino H; Fukuhara T; Kobayashi T; Naeshiro N; Honda Y; Tsuge M; Hiramatsu A; Imamura M; Hyogo H; Kawakami Y; Yoshimatsu R; Yamagami T; Awai K; Chayama K J Gastroenterol Hepatol; 2015 Apr; 30(4):726-32. PubMed ID: 25311578 [TBL] [Abstract][Full Text] [Related]
3. Assessment of Outcome of Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma by the Combination of RECIST and Tumor Markers. Hatooka M; Kawaoka T; Aikata H; Honda F; Nakamura Y; Nakano N; Morio K; Fukuhara T; Kobayashi T; Nagaoki Y; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Awai K; Chayama K Hiroshima J Med Sci; 2016 Sep; 65(2):25-33. PubMed ID: 29989682 [TBL] [Abstract][Full Text] [Related]
4. Early on-treatment predictions of clinical outcomes using alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with advanced hepatocellular carcinoma. Lee MH; Kim SU; Kim DY; Ahn SH; Choi EH; Lee KH; Lee DY; Seong J; Han KH; Chon CY; Park JY J Gastroenterol Hepatol; 2012 Feb; 27(2):313-22. PubMed ID: 21793906 [TBL] [Abstract][Full Text] [Related]
6. Pilot Study of Hepatic Arterial Infusion Chemotherapy with Interferon-beta and 5-fluorouracil: A New Chemotherapy for Patients with Advanced Hepatocellular Carcinoma. Shakado S; Iwata K; Tsuchiya N; Kunimoto H; Yotsumoto K; Fukunaga A; Kuno S; Tanaka T; Sakurai K; Iwashita H; Hirano G; Yokoyama K; Morihara D; Nishizawa S; Takeyama Y; Irie M; Sohda T; Kora S; Yoshimitsu K; Sakisaka S Hepatogastroenterology; 2014 May; 61(131):557-62. PubMed ID: 26176035 [TBL] [Abstract][Full Text] [Related]
7. Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma. Kawaoka T; Aikata H; Hyogo H; Morio R; Morio K; Hatooka M; Fukuhara T; Kobayashi T; Naeshiro N; Miyaki D; Hiramatsu A; Imamura M; Kawakami Y; Takahashi S; Waki K; Tsuji K; Kohno H; Kohno H; Moriya T; Chayama K J Dig Dis; 2015 Sep; 16(9):505-12. PubMed ID: 26121102 [TBL] [Abstract][Full Text] [Related]
8. Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial. Hatooka M; Kawaoka T; Aikata H; Inagaki Y; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Awai K; Masaki K; Waki K; Kohno H; Kohno H; Moriya T; Nagaoki Y; Tamura T; Amano H; Katamura Y; Chayama K BMC Cancer; 2018 Jun; 18(1):633. PubMed ID: 29866075 [TBL] [Abstract][Full Text] [Related]
9. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Ando E; Tanaka M; Yamashita F; Kuromatsu R; Yutani S; Fukumori K; Sumie S; Yano Y; Okuda K; Sata M Cancer; 2002 Aug; 95(3):588-95. PubMed ID: 12209752 [TBL] [Abstract][Full Text] [Related]
10. Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis. Eun JR; Lee HJ; Moon HJ; Kim TN; Kim JW; Chang JC Scand J Gastroenterol; 2009; 44(12):1477-86. PubMed ID: 19958061 [TBL] [Abstract][Full Text] [Related]
11. Early Decreases in α-Fetoprotein and Des-γ-carboxy Prothrombin Predict the Antitumor Effects of Hepatic Transarterial Infusion Chemotherapy with Cisplatin (CDDP) Powder in Patients with Advanced Hepatocellular Carcinoma. Hatanaka T; Kakizaki S; Shimada Y; Takizawa D; Katakai K; Yamazaki Y; Sato K; Kusano M; Yamada M Intern Med; 2016; 55(16):2163-71. PubMed ID: 27522991 [TBL] [Abstract][Full Text] [Related]
12. The tumor marker score is an independent predictor of survival in patients with recurrent hepatocellular carcinoma. Okamura Y; Ashida R; Ito T; Sugiura T; Mori K; Uesaka K Surg Today; 2015 Dec; 45(12):1513-20. PubMed ID: 25527455 [TBL] [Abstract][Full Text] [Related]
13. A randomized study of cisplatin and 5-FU hepatic arterial infusion chemotherapy with or without adriamycin for advanced hepatocellular carcinoma. Song MJ; Bae SH; Chun HJ; Choi JY; Yoon SK; Park JY; Han KH; Kim YS; Yim HJ; Um SH; Chung WJ; Hwang JS; Cho SB; Eun JR Cancer Chemother Pharmacol; 2015 Apr; 75(4):739-46. PubMed ID: 25663125 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib. Kawaoka T; Aikata H; Murakami E; Nakahara T; Naeshiro N; Tanaka M; Honda Y; Miyaki D; Nagaoki Y; Takaki S; Hiramatsu A; Waki K; Takahashi S; Chayama K Oncology; 2012; 83(4):192-200. PubMed ID: 22890083 [TBL] [Abstract][Full Text] [Related]
15. Serum vascular endothelial growth factor as a predictor of response and survival in patients with advanced hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy. Niizeki T; Sumie S; Torimura T; Kurogi J; Kuromatsu R; Iwamoto H; Aino H; Nakano M; Kawaguchi A; Kakuma T; Sata M J Gastroenterol; 2012 Jun; 47(6):686-95. PubMed ID: 22382631 [TBL] [Abstract][Full Text] [Related]
16. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma according to Child-Pugh classification. Miyaki D; Aikata H; Honda Y; Naeshiro N; Nakahara T; Tanaka M; Nagaoki Y; Kawaoka T; Takaki S; Waki K; Hiramatsu A; Takahashi S; Ishikawa M; Kakizawa H; Awai K; Chayama K J Gastroenterol Hepatol; 2012 Dec; 27(12):1850-7. PubMed ID: 23020312 [TBL] [Abstract][Full Text] [Related]
17. IL-28B variant as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy. Terashima T; Honda M; Toyama T; Shimakami T; Shimizu R; Takatori H; Arai K; Kawaguchi K; Kitamura K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Kaneko S J Gastroenterol Hepatol; 2020 Oct; 35(10):1813-1820. PubMed ID: 32180251 [TBL] [Abstract][Full Text] [Related]
18. Post-ablation des-gamma-carboxy prothrombin level predicts prognosis in hepatitis B-related hepatocellular carcinoma. Lee S; Rhim H; Kim YS; Kang TW; Song KD Liver Int; 2016 Apr; 36(4):580-7. PubMed ID: 26503910 [TBL] [Abstract][Full Text] [Related]
19. Early α-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma. Kim BK; Ahn SH; Seong JS; Park JY; Kim DY; Kim JK; Lee DY; Lee KH; Han KH Liver Int; 2011 Mar; 31(3):369-76. PubMed ID: 21083802 [TBL] [Abstract][Full Text] [Related]
20. Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A. Lee BH; Lee DS; Cho CW; Yun SS World J Surg Oncol; 2019 Aug; 17(1):143. PubMed ID: 31416447 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]